注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Morphic Holding Inc是一家生物制药公司。该公司致力于发现和开发用于治疗严重慢性疾病的口服小分子整合素疗法,包括自身免疫、心血管和代谢疾病、纤维化和癌症。该公司的Morphic整合素技术平台(MInT平台)有助于开发新的候选产品,旨在实现口服给药所需的效力、高选择性和药物特性。该公司正在推进其管道,包括其主要候选产品MORF-057,这是一种影响炎症的α4β7特异性整合素抑制剂,用于治疗炎症性肠病(IBD)的临床开发。其还开发了选择性口服αvβ6特异性整合素抑制剂,用于治疗纤维化疾病,包括特发性肺纤维化。其子公司Morphic Therapeutic, Inc.是一家生物制药公司。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Gustav A. Christensen | 73 | 2016 | Independent Chairman |
Yury V. Popov | - | - | Member of Scientific Advisory Board |
Scott L. Friedman | - | - | Member of Scientific Advisory Board |
Susannah Gray | 61 | 2021 | Independent Director |
Norbert W. Bischofberger | 66 | 2019 | Independent Director |
Martin William Edwards | 66 | 2020 | Independent Director |
Amir H. Nashat | 50 | 2017 | Independent Director |
Albert J. Robichaud | 62 | - | Member of Scientific Advisory Board |
Ulrich H. von Andrian-Werburg | - | - | Member of Scientific Advisory Board |
Shelia M. Violette | - | - | Member of Scientific Advisory Board |
Joseph P. Slattery | 58 | 2019 | Independent Director |
Brian G. Feagan | - | - | Member of Clinical Advisory Board |
Nisha Nanda | 48 | 2021 | Independent Director |
Silvio Danese | - | - | Member of Clinical Advisory Board |
Laurent Peyrin-Biroulet | - | - | Member of Clinical Advisory Board |
Bruce E. Sands | - | - | Member of Clinical Advisory Board |
Stefan Schreiber | 61 | 2023 | Member of Clinical Advisory Board |
Praveen P. Tipirneni | 56 | 2015 | CEO, MD & Director |
Timothy A. Springer | 76 | 2014 | Founder, Independent Director & Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核